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Mutations in CHEK2 predispose to a range of cancer
types including breast cancer. A meta-analysis of all
association studies estimated the risk of breast cancer
among carriers of 1100delC to be increased by 2.7-fold
(9) and increased by 4.7-fold among carriers with a posi-
tive family history of breast cancer (Weischer M et al.
CHEK2*1100delC genotyping for clinical assessment of
breast cancer risk: meta-analysis of 26,000 patients cases
and 27,000 controls. J Clin Oncol 2008; 26: 542-548).
We estimated the risk of breast cancer in a woman who
has a CHEK2 mutation depending on her family history
of breast cancer. Out data suggest that carriers of a
truncating mutation of CHEK2 (IVS2+1G>A, del5395,
1100delC) have 2.9 – fold increased risk of breast cancer
in the Polish population. The risk was higher for women
with at least one first-degree relative with breast cancer
(OR = 4.5), and for women with at least one second-
degree relative with breast cancer (OR = 3.5). If both a
first- and second-degree relative was affected with breast
cancer, the odds ratio was 6.4. We estimate the lifetime
risks for carriers of CHEK2 truncating mutations to be
from 21 to 37% depending family history of breast can-
cer in first- and second degree relatives. CHEK2 muta-
tion screening detects a clinically meaningful risk of
breast cancer.
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